EP0506836B1 - BCRF1 PROTEINS AS INHIBITORS OF INTERFERON-$g(g) - Google Patents

BCRF1 PROTEINS AS INHIBITORS OF INTERFERON-$g(g) Download PDF

Info

Publication number
EP0506836B1
EP0506836B1 EP91902258A EP91902258A EP0506836B1 EP 0506836 B1 EP0506836 B1 EP 0506836B1 EP 91902258 A EP91902258 A EP 91902258A EP 91902258 A EP91902258 A EP 91902258A EP 0506836 B1 EP0506836 B1 EP 0506836B1
Authority
EP
European Patent Office
Prior art keywords
bcrf1
protein
interferon
host
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP91902258A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0506836A1 (en
Inventor
Kevin W. Moore
Robert A. Kastelein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP0506836A1 publication Critical patent/EP0506836A1/en
Application granted granted Critical
Publication of EP0506836B1 publication Critical patent/EP0506836B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Definitions

  • the invention relates generally to methods and compositions for treating diseases associated with excessive interferon- ⁇ (IFN- ⁇ ) production, and more particularly to methods and compositions employing the Epstein-Barr virus (EBV) protein BCRF1 for effectively reducing levels of IFN- ⁇ .
  • IFN- ⁇ interferon- ⁇
  • EBV Epstein-Barr virus
  • the immune system comprises a highly interactive complex of tissues, cell types, and soluble factors. Recently, it has been suggested that several diseases and immune disorders may be associated with imbalances among certain components of the immune system, particularly cytokines: e.g. Mosmann et al., Ann. Rev. Immunol., Vol. 7, pgs. 145-173 (1989); Cher et al., J. Immunol. , Vol. 138, pgs. 3688-3694 (1987); Mosmann et al., Immunol. Today , Vol. 8, pgs. 223-227 (1987); and Heinzel et al., J. Exp. Med. , Vol. 169, pgs. 59-72 (1989).
  • cytokines e.g. Mosmann et al., Ann. Rev. Immunol., Vol. 7, pgs. 145-173 (1989); Cher et al., J. Immunol. , Vol. 138, pgs
  • IFN- ⁇ gamma interferon
  • MHC major histocompatibility complex
  • IFN- ⁇ may also play a role in allergy by its ability to increase the number and density of Fc ⁇ receptors on monocytes; it has been implicated in the pathogenesis of sarcoidosis and psoriasis; and it is believed to augment cell-mediated immunity, which plays a major role in tissue rejection in allogenic transplant patients.
  • the availability of compounds capable of reducing IFN- ⁇ levels would be highly advantageous for treatment of diseases associated with inappropriate immune responses, such as some parasitic diseases, allergy, and MHC-associated immune disorders, including rheumatoid arthritis, systemic lupus erythematosus (SLE), myasthenia gravis, insulin-dependent diabetes mellitus, thyroiditis, and the like.
  • diseases associated with inappropriate immune responses such as some parasitic diseases, allergy, and MHC-associated immune disorders, including rheumatoid arthritis, systemic lupus erythematosus (SLE), myasthenia gravis, insulin-dependent diabetes mellitus, thyroiditis, and the like.
  • the invention relates to methods and compositions for treating diseases associated with high levels of IFN- ⁇ production.
  • the method of the invention comprises the step of administering a disease-controlling amount of a BCRF1, a protein derived from the Epstein-Barr virus.
  • the invention further includes expression vectors for producing recombinant BCRF1, purified BCRF1, and pharmaceutical compositions for use with the method.
  • the BCRF1 used with the invention is selected from the group of mature polypeptides of the open reading frame defined by the amino acid sequence shown in SEQ ID NO: 1, wherein the abbreviations indicate the L forms of the amino acids, and the amino acids are listed starting from the N-terminus.
  • Figure 1 is a diagrammatic illustration of a mammalian expression vector useful in the production of BCRF1.
  • Figure 2 is a diagrammatic illustration of a bacterial expression vector useful in the production of BCRF1.
  • the invention relates to methods and compositions for treating diseases associated with excessive IFN- ⁇ production.
  • the invention is based in part on the discovery that the nucleic acid sequence encoding a recently discovered protein, designated cytokine synthesis inhibitory factor (CSIF), possesses a high degree of homology with the EBV BCRF1 open reading frame.
  • EBV is a human herpesvirus endemic in all human populations, and has been associated with several diseases: e.g. Dillner et al., Adv. Cancer Res. , Vol 50, pgs. 95-158 (1988); Thorley-Lawson, Biochim. Biophys. Acta , Vol. 948, pgs. 263-286 (1988); and Tasato, Adv. Cancer Res.
  • EBV has a double-stranded DNA genome of about 172 kilobases [Baer et al., Nature , Vol. 310, pgs. 207-211 (1984)].
  • the genome contains many open reading frames apparently corresponding to proteins produced by EBV, one of which is BCRF1.
  • the invention includes mature polypeptides, or proteins, of the BCRF1 open reading frame.
  • an open reading frame usually encodes a polypeptide that consists of a mature or secreted product covalently linked at its N-terminus to a signal peptide.
  • the signal peptide is cleaved prior to secretion of the mature, or active, polypeptide.
  • the cleavage site can be predicted with a high degree of accuracy from empirical rules [ e.g. , von Heijne, Nucleic Acids Research , Vol. 14, pgs. 4683-4690 (1986)], and the precise amino acid composition of the signal peptide does not appear to be critical to its function [ e.g.
  • a wide range of expression systems can be used to produce the proteins of the invention.
  • Possible types of host cells include, but are not limited to, bacterial, yeast, insect, mammalian, and the like.
  • Many reviews are available which provide guidance for making choices and/or modifications of specific expression systems: e.g. (to name a few), de Boer and Shepard, "Strategies for Optimizing Foreign Gene Expression in Escherichia coli," pgs. 205-247, in Kroon, ed. Genes: Structure and Expression (John Wiley & Sons, New York, 1983), review several E. coli expression systems; Kucherlapati et al., Critical Reviews in Biochemistry , Vol. 16, Issue 4, pgs.
  • E. coli expression system is disclosed by Riggs in U.S. Patent 4,431,739, which is incorporated by reference.
  • Particularly useful prokaryotic promoters for high expression in E. coli are the tac promoter, disclosed by de Boer in U.S. Patent 4,551,433, which is incorporated herein by reference, and the pL promoter, disclosed by Remaut et al., Gene , Vol 15, pgs. 81-93 (1981), which is incorporated by reference.
  • Secretion expression vectors are also available for E. coli hosts. Particularly useful are the pIN-III-ompA vectors, disclosed by Ghrayeb et al., in EMBO J. , Vol. 3, pgs.
  • expression systems comprising cells derived from multicellular organism may also be used to produce proteins of the invention.
  • mammalian expression systems because their post-translational processing machinery is more likely to produce biologically active mammalian proteins.
  • DNA tumor viruses have been used as vectors for mammalian hosts. Particularly important are the numerous vectors which comprise SV40 replication, transcription, and/or translation control sequences coupled to bacterial replication control sequences, e.g. the pcD vectors developed by Okayama and Berg, disclosed in Mol. Cell. Biol. , Vol. 2, pgs. 161-170 (1982) and Mol. Cell. Biol. , Vol. 3, pgs. 280-289 (1983), and improved by Takebe et al., Mol. Cell. Biol. , Vol. 8, pgs. 466-472 (1988). Accordingly, these references are incorporated herein by reference.
  • SV40-based mammalian expression vectors include those containing adenovirus regulatory elements, disclosed by Kaufman and Sharp, in Mol. Cell. Biol. , Vol. 2, pgs. 1304-1319 (1982), and by Clark et al., in U.S. patent 4,675,285, both of which are incorporated herein by reference. Monkey cells are usually the preferred hosts for the above vectors. Such vectors containing the SV40 ori sequences and an intact A gene can replicate autonomously in monkey cells (to give higher copy numbers and/or more stable copy numbers than nonautonomously replicating plasmids).
  • vectors containing the SV40 ori sequences without an intact A gene can replicate autonomously to high copy numbers (but not stably) in COS7 monkey cells, described by Gluzman, Cell , Vol. 23, pgs. 175-182 (1981) and available from the ATCC (accession no. CRL 1651).
  • the above SV40-based vectors are also capable of transforming other mammalian cells, such as mouse L cells, by integration into the host cell DNA.
  • the biological activity of the BCRF1s of the invention is readily determined in IFN- ⁇ inhibition assays.
  • Such assays require a cell line or cell population that synthesizes IFN- ⁇ .
  • peripheral blood lymphocytes PBLs
  • PHA phytohemagglutinin
  • the assay works as follows: The PHA-stimulated PBLs are divided into two equal parts. To one part, a sample containing a BCRF1 is added. The other part serves as a control. After several days the supernatants of both cultures are tested for IFN- ⁇ .
  • the readout of the assay can be the amount of IFN- ⁇ mRNA transcribed, for example, as measured by RNA-blotting, PCR, or like methodology.
  • PBLs are obtained using standard techniques, e.g. Mishell et al., eds., Selected Methods in Cellular Immumology (Freeman, New York, 1980).
  • polypeptides of the present invention When polypeptides of the present invention are expressed in soluble form, for example as a secreted product of transformed yeast or mammalian cells, they can be purified according to standard procedures of the art, including steps of ammonium sulfate precipitation, ion exchange chromatography, gel filtration, electrophoresis, affinity chromatography, and/or the like; e.g. Enzyme Purification and Related Techniques, Methods in Enzymology , 22:233-577 (1977), and Scopes, Protein Purification: Principles and Practice (Springer-Verlag, New York, 1982) provide guidance in such purifications.
  • polypeptides of the invention when expressed in insoluble form, for example as aggregates, inclusion bodies or the like, they can be purified by standard procedures in the art, including separating the inclusion bodies from disrupted host cells by centrifugation, solubilizing the inclusion bodies with chaotropic agents and with reducing agents, diluting the solubilized mixture, and lowering the concentration of chaotropic agent and reducing agent so that the polypeptide takes on a biologically active conformation.
  • an effective amount means an amount sufficient to ameliorate a symptom of a disease condition mediated by excessive IFN- ⁇ .
  • the effective amount for a particular patient may vary depending on such factors as the state of the disease condition being treated, the overall health of the patient, the method of administration, the severity of side-effects, and the like.
  • BCRF1 is administered as a pharmaceutical composition comprising an effective amount of BCRF1 and a pharmaceutical carrier or excipient.
  • a pharmaceutical carrier can be any compatible, non-toxic substance suitable for delivering the compositions of the invention to a patient.
  • compositions useful for parenteral administration of such drugs are well known, e.g. Remington's Pharmaceutical Science, 15th Ed. (Mack Publishing Company, Easton, PA 1980).
  • compositions of the invention may be introduced into a patient's body by implantable drug delivery system: e.g. Urquhart et al., Ann. Rev. Pharmacol. Toxicol. , Vol. 24, pgs. 199-236 (1984); Lewis, ed. Controlled Release of Pesticides and Pharmaceuticals (Plenum Press, New York, 1981); U.S. patent 3,773,919; U.S. patent 3,270,960; and the like.
  • implantable drug delivery system e.g. Urquhart et al., Ann. Rev. Pharmacol. Toxicol. , Vol. 24, pgs. 199-236 (1984); Lewis, ed. Controlled Release of Pesticides and Pharmaceuticals (Plenum Press, New York, 1981); U.S. patent 3,773,919; U.S. patent 3,270,960; and the like.
  • the BCRF1 When administered parenterally, the BCRF1 is formulated in a unit dosage injectable form (e.g. , a solution, suspension, or emulsion) in association with a pharmaceutical carrier.
  • a pharmaceutical carrier e.g. , a solution, suspension, or emulsion
  • Such carriers are inherently nontoxic and nontherapeutic. Examples of such carriers are normal saline, Ringer's solution, dextrose solution, and Hank's solution. Nonaqueous carriers such as fixed oils and ethyl oleate may also be used. A preferred carrier is 5% dextrose/saline.
  • the carrier may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, e.g. , buffers and preservatives.
  • BCRF1 is preferably formulated in purified form substantially free of aggregates and other proteins at a concentration in the range of about 5 to 20 ⁇ g/ml.
  • BCRF1 is administered by continuous infusion so that an amount in the range of about 50-800 ⁇ g is delivered per day ( i.e. about 1-16 ⁇ g/kg/day).
  • the daily infusion rate may be varied based on monitoring of side effects, blood cell counts, and the like.
  • a gene encoding the open reading frame for BCRF1 was amplified by polymerase chain reaction using primers that allowed later insertion of the amplified fragment into an Eco RI-digested pcD(SR ⁇ ) vector ( Figure 1).
  • the coding strand of the inserted fragment is shown in SEQ ID NO. 2.
  • Clones carrying the insert in the proper orientation were identified by expression of BCRF1 and/or the electrophoretic pattern of restriction digests.
  • One such vector carrying the BCRF1 gene was designated pBCRF1(SR ⁇ ) and was deposited with the ATCC under accession number 68193.
  • pBCRF1(SR ⁇ ) was amplified in E. coli MC1061, isolated by standard techniques, and used to transfect COS 7 monkey cells as follows: One day prior to transfection, approximately 1.5 x 106 COS 7 monkey cells were seeded onto individual 100 mm plates in Dulbecco's modified Eagle medium (DME) containing 5% fetal calf serum (FCS) and 2 mM glutamine.
  • DME Dulbecco's modified Eagle medium
  • FCS 5% fetal calf serum
  • COS 7 cells were removed from the dishes by incubation with trypsin, washed twice in serum-free DME, and suspended to 107 cells/ml in serum-free DME. A 0.75 ml aliquot was mixed with 20 ⁇ g DNA and transferred to a sterile 0.4 cm electroporation cuvette. After 10 minutes, the cells were pulsed at 200 volts, 960 ⁇ F in a BioRad Gene Pulser unit. After another 10 minutes, the cells were removed from the cuvette and added to 20 ml of DME containing 5% FCS, 2mM glutamine, penicillin, streptomycin, and gentamycin. The mixture was aliquoted to four 100 mm tissue culture dishes.
  • a gene encoding a mature BCRF1 of the sequence given in SEQ ID NO. 3 may be expressed in E. coli :
  • the cDNA insert of pBCRF1(SR ⁇ ) is recloned into an M13 plasmid where it is altered twice by site-directed mutagenesis: first to form a Cla I site at the 5'-end of the coding region for the mature BCRF1 polypeptide, and second to form a Bam HI site at the 3'-end of the coding region for the mature BCRF1 polypeptide.
  • the mutated sequence is then readily inserted into the TRPC11 expression vector described below.
  • the TRPC11 vector was constructed by ligating a synthetic consensus RBS fragment to Cla I linkers (ATGCAT) and by cloning the resulting fragments into Cla I-restricted pMT11hc (which had been previously modified to contain the Cla I site).
  • pMT11hc is a small (2.3 kilobase) high copy, AMP R , TET S derivative of pBR322 that bears the ⁇ VX plasmid Eco RI- Hind III polylinker region.
  • TRPC11 is employed as a vector for BCRF1 by first digesting it with Cla I and Bam HI, purifying it, and then mixing it in a standard ligation solution with the Cla I- Bam HI fragment of the M13 containing the nucleotide sequence coding for the mature BCRF1.
  • the insert-containing TRPC11 referred to as TRPC11-BCRF1, is propagated in E. coli K12 strain JM101, e.g. available from the ATCC under accession number 33876.
  • the Deposit has been modified to conform to the requirements of the Budapest Treaty on the Deposit of Microorganisms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP91902258A 1989-12-20 1990-12-18 BCRF1 PROTEINS AS INHIBITORS OF INTERFERON-$g(g) Expired - Lifetime EP0506836B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45393189A 1989-12-20 1989-12-20
US453931 1989-12-20
PCT/US1990/007288 WO1991009127A1 (en) 1989-12-20 1990-12-18 BCRF1 PROTEINS AS INHIBITORS OF INTERFERON-$g(g)

Publications (2)

Publication Number Publication Date
EP0506836A1 EP0506836A1 (en) 1992-10-07
EP0506836B1 true EP0506836B1 (en) 1994-09-28

Family

ID=23802631

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91902258A Expired - Lifetime EP0506836B1 (en) 1989-12-20 1990-12-18 BCRF1 PROTEINS AS INHIBITORS OF INTERFERON-$g(g)

Country Status (27)

Country Link
US (2) US5627155A (fi)
EP (1) EP0506836B1 (fi)
JP (1) JP2648236B2 (fi)
KR (1) KR960015199B1 (fi)
CN (1) CN1057012C (fi)
AT (1) ATE112317T1 (fi)
AU (1) AU7899694A (fi)
CA (1) CA2071907C (fi)
CZ (1) CZ283049B6 (fi)
DE (1) DE69013011T2 (fi)
DK (1) DK0506836T3 (fi)
ES (1) ES2064082T3 (fi)
FI (1) FI104883B (fi)
HK (1) HK185396A (fi)
HU (1) HU215909B (fi)
IE (1) IE72203B1 (fi)
IL (1) IL96715A0 (fi)
MX (1) MX9203409A (fi)
MY (1) MY107449A (fi)
NO (1) NO305703B1 (fi)
NZ (1) NZ236512A (fi)
OA (1) OA09703A (fi)
PH (1) PH31669A (fi)
PT (1) PT96231B (fi)
SK (1) SK279830B6 (fi)
WO (1) WO1991009127A1 (fi)
ZA (1) ZA9010188B (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
AU6643690A (en) * 1989-10-23 1991-05-16 Schering Corporation Polypeptide inhibitors of gamma interferon
US6106823A (en) * 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
KR100207766B1 (ko) * 1991-01-16 1999-07-15 둘락 노먼 씨. 신생물 질환 치료용 인터루킨-10 조성물
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
ES2138976T3 (es) * 1991-08-06 2000-02-01 Schering Corp Uso de analogos o antagonistas de interleucina-10 para tratar la toxicidad inducida por endotoxinas o superantigenos.
ATE222291T1 (de) * 1992-03-13 2002-08-15 Organon Teknika Bv Epstein-barr-virus verwandte peptide und nukleinsäuresegmenten
US6008327A (en) * 1992-03-13 1999-12-28 Akzo Nobel, N.V. Peptides and nucleic acid sequences related to the Epstein Barr virus
AU3801193A (en) * 1992-03-20 1993-10-21 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
DE69330966T2 (de) * 1993-07-23 2002-06-06 Wolf, Hans DNA-Sequenzen des Epstein-Barr Virus kodierend für ein diagnostisch relevantes Virus-Hüllprotein, durch PCR erhaltene Expressionsklone und Verwendung dieses rekombinanten Antigens in diagnostischen Tests
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
DE69840216D1 (de) * 1997-08-08 2008-12-24 Celmed Oncology Usa Inc Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden
AU2012340624B2 (en) 2011-11-23 2017-08-24 Amgen Inc. Methods of treatment using an antibody against interferon gamma
WO2022016509A1 (zh) * 2020-07-24 2022-01-27 阎忠扬 一种用以筛选药物的方法，以及该药物用于治疗牛皮癣的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583564D1 (de) * 1984-08-23 1991-08-29 Hans Joachim Wolf Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
US5256768A (en) * 1985-12-13 1993-10-26 The Johns Hopkins University Expression of antigenic Epstein-Barr virus polypeptides in bacteria and their use in diagnostics

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Hudson et al., Virology 147: 81-98 (1985) *
Journal of Experimental Medicine, vol. 170, 1 Dec. 1989, The Rockefeller University Press, D.F. Fiorentino et al.: "Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Thl clones", pages 2081-2095 *
Journal of Experimental Medicine, vol. 172, no. 6, 1. Dec. 90, The Rockefeller University Press, by Ning Fei Go et al.: "Interleukin 10, a novel B cell stimulatory factor: Unresponsiveness of X chromosomelinked imunodeficiency B cells", pages 1625-1634 *
Nucleic Acids Research, vol. 14, no. 11, 1986, IRL Press Ltd. (Oxford, GB), G. von Heijne: "A new method for predicting signal sequence cleavage sites", pages 4683-4690. *
Science, vol. 248, no. 4960. 8 June 90, K.W. Moore et al.: "Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr Virus Gene BCRFI", pages 1230-1234. *
Science, vol. 250, 9. Nov. 1990, D.-H. Hsu et al.: "Expression of interleukin-10 acitivity by Epstein-Barr Virus Protein BCRF1", pages 830-832. *

Also Published As

Publication number Publication date
JP2648236B2 (ja) 1997-08-27
WO1991009127A1 (en) 1991-06-27
OA09703A (en) 1993-08-30
AU652732B2 (en) 1994-09-08
AU7899694A (en) 1995-02-09
PT96231B (pt) 1998-09-30
IE904588A1 (en) 1991-07-03
ES2064082T3 (es) 1995-01-16
PH31669A (en) 1999-01-18
ZA9010188B (en) 1991-08-28
DE69013011T2 (de) 1995-02-23
CN1052608A (zh) 1991-07-03
CN1057012C (zh) 2000-10-04
FI922770A0 (fi) 1992-06-16
CZ635190A3 (en) 1997-09-17
HK185396A (en) 1996-10-11
IL96715A0 (en) 1991-09-16
NZ236512A (en) 1997-07-27
FI104883B (fi) 2000-04-28
ATE112317T1 (de) 1994-10-15
AU7063691A (en) 1991-07-18
JPH05503846A (ja) 1993-06-24
US5736390A (en) 1998-04-07
CZ283049B6 (cs) 1997-12-17
US5627155A (en) 1997-05-06
NO305703B1 (no) 1999-07-12
DK0506836T3 (da) 1994-11-28
MY107449A (en) 1995-12-31
PT96231A (pt) 1991-09-30
HUT65369A (en) 1994-05-02
HU215909B (hu) 1999-03-29
NO922456D0 (no) 1992-06-19
SK635190A3 (en) 1999-04-13
KR960015199B1 (ko) 1996-11-01
SK279830B6 (sk) 1999-04-13
CA2071907A1 (en) 1991-06-21
FI922770A (fi) 1992-06-16
HU9202075D0 (en) 1992-10-28
CA2071907C (en) 2000-08-08
IE72203B1 (en) 1997-04-09
NO922456L (no) 1992-06-19
DE69013011D1 (de) 1994-11-03
MX9203409A (es) 1992-07-01
EP0506836A1 (en) 1992-10-07

Similar Documents

Publication Publication Date Title
US5776451A (en) Use of interleukin-10 in adoptive immunotherapy of cancer
EP0506836B1 (en) BCRF1 PROTEINS AS INHIBITORS OF INTERFERON-$g(g)
AU652030B2 (en) Treatment of neoplastic disease with interleukin-10
WO1993018783A1 (en) Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
AU652732C (en) BCRF1 proteins as inhibitors of interferon-gamma
US6106823A (en) Treatment of neoplastic disease with interleukin-10
AU650013B2 (en) BCRF1 antagonists for treating Epstein-Barr virus infections

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920612

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19930514

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 112317

Country of ref document: AT

Date of ref document: 19941015

Kind code of ref document: T

REF Corresponds to:

Ref document number: 69013011

Country of ref document: DE

Date of ref document: 19941103

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

ITF It: translation for a ep patent filed
ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2064082

Country of ref document: ES

Kind code of ref document: T3

EAL Se: european patent in force in sweden

Ref document number: 91902258.2

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3014120

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20010919

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20010921

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20011011

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20011017

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20011105

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20011204

Year of fee payment: 12

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20020103

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20020117

Year of fee payment: 12

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021218

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021231

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030131

BERE Be: lapsed

Owner name: *SCHERING CORP.

Effective date: 20021231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030707

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20030701

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20031105

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20031201

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20031215

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20031230

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050701

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20041218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050831

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20051218

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20041220